HC Wainwright Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 250.77% from the company’s current price.

DYN has been the topic of a number of other reports. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Finally, Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Stock Down 32.0 %

DYN traded down $7.37 on Friday, reaching $15.68. The company had a trading volume of 3,705,905 shares, compared to its average volume of 1,425,354. Dyne Therapeutics has a 1 year low of $15.22 and a 1 year high of $47.45. The stock has a market capitalization of $1.60 billion, a PE ratio of -4.40 and a beta of 1.16. The stock has a 50-day moving average price of $27.29 and a 200-day moving average price of $34.15.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts expect that Dyne Therapeutics will post -3.45 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dirk Kersten sold 23,671 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares in the company, valued at $3,522,698.20. This represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,742 shares of company stock valued at $1,443,246 in the last ninety days. 20.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new position in Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $62,000. Finally, KBC Group NV grew its position in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.